Phase 1 Metastatic Gastric Cancer Clinical Trials
6 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–6 of 6 trials
Recruiting
Phase 1
A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.
Metastatic Breast CancerMetastatic Gastric CancerEndometrial Cancer Metastatic
Vall d'Hebron Institute of Oncology15 enrolled2 locationsNCT07593820
Recruiting
Phase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
Metastatic Breast CancerEndometrial CancerAdvanced Solid Tumor+6 more
Institut Paoli-Calmettes27 enrolled1 locationNCT05143970
Recruiting
Phase 1
BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
Gastroesophageal Junction AdenocarcinomaAdvanced or Metastatic Gastric Cancer
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.80 enrolled1 locationNCT06773312
Recruiting
Phase 1Phase 2
Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer
Metastatic Gastric Cancer
CNBG-Virogin Biotech (Shanghai) Ltd.43 enrolled1 locationNCT06008925
Completed
Phase 1
A Randomized, Single-Blind, Single-Dose, 3-Arm, Parallel Group Study to Determine the Pharmacokinetic Equivalence of ABP 980 and Trastuzumab (Herceptin "(Registered Trademark)" ) in Healthy Male Subjects
To determine the safety, tolerability, and immunogenicity of ABP 980 in healthy subjects compared with FDA-licensed trastuzumab and EU-authorized trastuzumab.
Trastuzumab received marketing authorization in the EU in 2000 and is approved for use in patients with Breast Cancer and Metastatic Gastric Cancer.Breast Cancer
Amgen Inc, USA.150 enrolled1 locationACTRN12614000400662